XAIR
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.80 · operating margin -378% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 34 722 titres (~199 998,72 $ US)
- Insiders
- Goodman Robert Scott
- Total bought
-
$199,999
Avg buy (VWAP, 90d window) $5.51 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-07-29
- Last synced
-
2026-08-03 21:36:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-29 | Goodman Robert Scott | Buy | 34,722 | $5.51 | $191,318 | Form 4 |
| 2026-07-29 | MOORHEAD DANIEL J | Buy | 4,340 | $5.51 | $23,913 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-08-03
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 3.3% | -44.9% | -112.8% | 0.0% | 0.0% | |
| Ebit Margin | -401.3% | -1227.0% | -5296.2% | 0.0% | 0.0% | |
| Ebitda Margin | -353.8% | -1130.6% | -5093.3% | 0.0% | 0.0% | |
| Operating Profit Margin | -378.2% | -1202.1% | -5436.2% | 0.0% | 0.0% | |
| Pretax Profit Margin | -447.1% | -1308.5% | -5547.5% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -447.1% | -1308.5% | -5547.5% | 0.0% | 0.0% | |
| Net Profit Margin | -433.0% | -1258.4% | -5197.8% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -433.0% | -1258.4% | -5197.8% | 0.0% | 0.0% | |
| Current Ratio | 3.804 | 3.204 | 3.798 | 3.004 | 8.677 | |
| Quick Ratio | 3.588 | 2.720 | 3.615 | 2.946 | 8.644 | |
| Solvency Ratio | -1.015 | -2.739 | -1.944 | -2.045 | -2.029 | |
| Cash Ratio | 1.035 | 0.933 | 0.984 | 1.474 | 7.491 | |
| Price To Earnings Ratio | -0.172 | -0.396 | -0.870 | -3.625 | -3.971 | |
| Price To Earnings Growth Ratio | 0.002 | 0.006 | 0.356 | -0.339 | -0.123 | |
| Forward Price To Earnings Growth Ratio | 0.002 | 0.006 | 0.356 | -0.339 | -0.123 | |
| Price To Earnings Diluted Ratio | -0.172 | -0.396 | -0.870 | -3.625 | -3.971 | |
| Price To Earnings Diluted Growth Ratio | 0.002 | 0.006 | 0.356 | -0.339 | -0.123 | |
| Price To Book Ratio | 0.935 | 1.358 | 2.092 | 5.336 | 2.358 | |
| Price To Sales Ratio | 0.746 | 4.980 | 45.205 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -0.299 | -0.418 | -0.848 | -5.485 | -6.995 | |
| Price To Operating Cash Flow Ratio | -0.316 | -0.483 | -0.935 | -6.129 | -7.412 | |
| Debt To Assets Ratio | 0.661 | 0.389 | 0.313 | 0.052 | 0.035 | |
| Debt To Equity Ratio | 3.817 | 0.860 | 0.712 | 0.095 | 0.048 | |
| Debt To Capital Ratio | 0.792 | 0.463 | 0.416 | 0.087 | 0.046 | |
| Long Term Debt To Capital Ratio | 0.779 | 0.404 | 0.370 | 0.003 | 0.003 | |
| Financial Leverage Ratio | 5.776 | 2.213 | 2.274 | 1.813 | 1.364 | |
| Working Capital Turnover Ratio | 0.525 | 0.171 | 0.032 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.787 | -7.644 | -4.843 | -1.669 | -2.160 | |
| Operating Cash Flow Sales Ratio | -2.363 | -10.315 | -48.330 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | 1.154 | 1.103 | 1.117 | 1.060 | |
| Debt Service Coverage Ratio | -6.938 | -11.546 | -15.903 | -72.299 | -25.086 | |
| Interest Coverage Ratio | -8.263 | -14.752 | -21.637 | -1,735.300 | -52.529 | |
| Short Term Operating Cash Flow Coverage Ratio | -45.247 | -62.755 | -70.019 | -42.592 | -24.956 | |
| Operating Cash Flow Coverage Ratio | -0.776 | -3.270 | -3.140 | -9.190 | -6.634 | |
| Capital Expenditure Coverage Ratio | -17.701 | -6.496 | -9.750 | -8.514 | -16.764 | |
| Dividend Paid And Capex Coverage Ratio | -17.701 | -6.496 | -9.750 | -8.514 | -16.764 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.823 | -0.608 | -0.997 | -3.037 | -2.218 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 3.3% | ▲48.2% | ▲34.2% |
| Ebit Margin | -401.3% | ▲825.7% | ▲983.6% |
| Ebitda Margin | -353.8% | ▲776.8% | ▲961.7% |
| Operating Profit Margin | -378.2% | ▲823.9% | ▲1025.1% |
| Pretax Profit Margin | -447.1% | ▲861.4% | ▲1013.5% |
| Continuous Operations Profit Margin | -447.1% | ▲861.4% | ▲1013.5% |
| Net Profit Margin | -433.0% | ▲825.5% | ▲944.8% |
| Bottom Line Profit Margin | -433.0% | ▲825.5% | ▲944.8% |
| Current Ratio | 3.804 | ▲0.600 | ▼-0.693 |
| Quick Ratio | 3.588 | ▲0.868 | ▼-0.715 |
| Solvency Ratio | -1.015 | ▲1.724 | ▲0.940 |
| Cash Ratio | 1.035 | ▲0.102 | ▼-1.348 |
| Price To Earnings Ratio | -0.172 | ▲0.224 | ▲1.635 |
| Price To Earnings Growth Ratio | 0.002 | ▼-0.004 | ▲0.022 |
| Forward Price To Earnings Growth Ratio | 0.002 | ▼-0.004 | ▲0.022 |
| Price To Earnings Diluted Ratio | -0.172 | ▲0.224 | ▲1.635 |
| Price To Earnings Diluted Growth Ratio | 0.002 | ▼-0.004 | ▲0.022 |
| Price To Book Ratio | 0.935 | ▼-0.423 | ▼-1.481 |
| Price To Sales Ratio | 0.746 | ▼-4.234 | ▼-9.440 |
| Price To Free Cash Flow Ratio | -0.299 | ▲0.120 | ▲2.510 |
| Price To Operating Cash Flow Ratio | -0.316 | ▲0.167 | ▲2.739 |
| Debt To Assets Ratio | 0.661 | ▲0.272 | ▲0.371 |
| Debt To Equity Ratio | 3.817 | ▲2.957 | ▲2.711 |
| Debt To Capital Ratio | 0.792 | ▲0.330 | ▲0.432 |
| Long Term Debt To Capital Ratio | 0.779 | ▲0.376 | ▲0.468 |
| Financial Leverage Ratio | 5.776 | ▲3.563 | ▲3.088 |
| Working Capital Turnover Ratio | 0.525 | ▲0.354 | ▲0.379 |
| Operating Cash Flow Ratio | -2.787 | ▲4.857 | ▲1.034 |
| Operating Cash Flow Sales Ratio | -2.363 | ▲7.952 | ▲9.839 |
| Free Cash Flow Operating Cash Flow Ratio | 1.056 | ▼-0.097 | ▼-0.042 |
| Debt Service Coverage Ratio | -6.938 | ▲4.608 | ▲19.416 |
| Interest Coverage Ratio | -8.263 | ▲6.489 | ▲358.233 |
| Short Term Operating Cash Flow Coverage Ratio | -45.247 | ▲17.509 | ▲3.867 |
| Operating Cash Flow Coverage Ratio | -0.776 | ▲2.494 | ▲3.826 |
| Capital Expenditure Coverage Ratio | -17.701 | ▼-11.205 | ▼-5.856 |
| Dividend Paid And Capex Coverage Ratio | -17.701 | ▼-11.205 | ▼-5.856 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.823 | ▼-0.215 | ▲0.713 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $5.7M | $18.5M | $52.4M | $202.3M | $171.5M | |
| Enterprise value | $22.4M | $25.5M | $58.9M | $176.8M | $94.7M | |
| EV / Sales | 2.91x | 6.88x | 50.78x | 0.00x | 0.00x | |
| EV / Op. cash flow | -1.23x | -0.67x | -1.05x | -5.36x | -4.09x | |
| EV / Free cash flow | -1.17x | -0.58x | -0.95x | -4.79x | -3.86x | |
| EV / EBITDA | -0.82x | -0.61x | -1.00x | -3.04x | -2.22x | |
| Net debt / EBITDA | -0.61x | -0.17x | -0.11x | 0.44x | 1.80x | |
| Current ratio | 3.80x | 3.20x | 3.80x | 3.00x | 8.68x | |
| Income quality | 0.55x | 0.79x | 0.93x | 0.56x | 0.54x | |
| Graham net-net | -$38 | -$41 | $74 | $270 | $933 | |
| Tax burden | 96.8% | 96.2% | 93.7% | 94.0% | 98.0% | |
| Interest burden | 111.4% | 106.6% | 104.7% | 100.1% | 101.8% | |
| Working capital | $18.3M | $11.0M | $32.4M | $39.6M | $82.2M | |
| Invested capital | $28.7M | $25.0M | $45.3M | $48.8M | $88.3M | |
| Return on assets | -94.0% | -155.1% | -105.8% | -81.2% | -43.5% | |
| Operating ROA | -88.8% | -102.4% | -100.2% | -62.0% | -58.3% | |
| Return on tangible assets | -96.7% | -161.7% | -108.5% | -83.2% | -44.3% | |
| Return on equity | -542.8% | -343.3% | -240.5% | -147.2% | -59.4% | |
| Return on invested capital | -98.1% | -170.9% | -135.2% | -103.9% | -45.4% | |
| Return on capital employed | -100.6% | -177.7% | -138.8% | -106.3% | -46.0% | |
| Earnings yield | -580.5% | -252.7% | -115.0% | -27.6% | -25.2% | |
| Free cash flow yield | -334.7% | -239.0% | -117.9% | -18.2% | -14.3% | |
| Capex / Op. cash flow | -5.6% | -15.4% | -10.3% | -11.7% | -6.0% | |
| Capex / Depreciation | 29.8% | 164.7% | 244.3% | 331.4% | 234.7% | |
| Capex / Sales | 13.3% | 158.8% | 495.7% | 0.0% | 0.0% | |
| SG&A / Sales | 248.1% | 702.2% | 3221.5% | 0.0% | 0.0% | |
| R&D / Sales | 133.4% | 455.0% | 2102.1% | 0.0% | 0.0% | |
| Stock comp / Sales | 68.8% | 246.9% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 2.9% | 4.1% | 2.5% | 2.4% | 1.9% | |
| Days sales outstanding | 57d | 85d | 173d | 0d | 0d | |
| Days payables outstanding | 119d | 133d | 288d | 1326d | 0d | |
| Operating cycle | 126d | 249d | 487d | 742d | 0d | |
| Cash conversion cycle | 7d | 116d | 199d | -583d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-69.0%EV / Sales ▼-57.6%EV / EBITDA ▼-35.4%EV / Op. cash flow ▼-0.566Earnings yield ▼-3.278
Profitability
Return on equity ▼-1.995Return on assets ▲+0.611Return on invested capital ▲+0.727Return on capital employed ▲+0.771Operating ROA ▲+0.136Income quality ▼-0.243Tax burden ▲+0.007
Efficiency
Days sales outstanding ▼-28.112Days payables outstanding ▼-13.808Operating cycle ▼-123.360Cash conversion cycle ▼-109.552Capex / Sales ▼-1.454R&D / Sales ▼-3.216
Balance-sheet strength
Current ratio ▲+0.600Net debt / EBITDA ▼-0.445Working capital ▲+7238000.000Invested capital ▲+3757000.000Intangibles / Total assets ▼-0.012
Change over 5 years
Valuation
Market cap ▼-96.7%EV / Sales n/aEV / EBITDA ▲+62.9%EV / Op. cash flow ▲+2.861Earnings yield ▼-5.553
Profitability
Return on equity ▼-4.834Return on assets ▼-0.504Return on invested capital ▼-0.527Return on capital employed ▼-0.546Operating ROA ▼-0.305Income quality ▲+0.010Tax burden ▼-0.012
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-4.873Net debt / EBITDA ▼-2.410Working capital ▼-63977000.000Invested capital ▼-59564000.000Intangibles / Total assets ▲+0.010
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-07-30 Beyond Oil Expands Commercial Rollout to a Second Ownership Group of Top-Tier U.S. Supermarket Brand VANCOUVER, British Columbia, July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing health risks associated with fried food while improving food quality, lowering operational costs, minimizing waste and enhancing sustainability, announces that, further to its news release dated March 30, 2026, it has been approved to expand its commercial rollout into another ownership group with 14 additional stores of a top-tier U.S. supermarket brand, ranked among North America''s top-30 food retailers by annual sales.1 Following the successful rollout with the first ownership group, Beyond Oil worked to fine-tune the program, ensure strong operator compliance and build an effective model for broader rollout.
- 2026-07-30 Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules GARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced that it has entered into a securities purchase agreement for the purchase and sale of (i) an aggregate of 167,011 shares of the Company''s common stock and accompanying warrants at a combined purchase price of $5.66 per share to certain institutional investors (“Purchase Price”) and a combined purchase price of $5.76 per share to certain of the Company''s directors and officers, and (ii) in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,638,835 shares of the Company''s common stock and accompanying warrants at a combined purchase price of $5.6599, representing the Purchase Price less the $0.0001 exercise price of each pre-funded warrant.
- 2026-06-26 Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
- 2026-06-26 Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026
- 2026-06-22 Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company''s management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day.
- 2026-06-10 Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.Y.
- 2026-06-10 Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p. m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.
- 2026-06-01 Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients'' lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company''s request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC''s (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026.